This model indicates that effectively and specifically activating the BTK-ADAP–dependent mTOR-STAT3 signaling axis to maintain the formation of PDPNhi PMs may represent a promising target for immunotherapies in inflammatory diseases such as sepsis. This evidence concerns the gene MTOR and Sepsis.